MarketPositioning Leverage the combined Amneal and Impax platform to approach healthcare providers and payers with a broad generics and branded biosimilars portfolio, emphasizing affordable access and comprehensive patient solutions.

ExpansionPotential Target facilities and regions where Amneal has recently expanded (Suffolk NY, New Jersey, New York) to align supply capabilities with demand, offering reliability in manufacturing capacity for approved iohexol variations and progesterone capsules.

ProductLaunch Capitalize on FDA-approved romidepsin injection and ongoing injectable opportunities to position as a partner for oncology and specialty injectable needs, facilitating faster time-to-market through established regulatory and manufacturing pathways.

CustomersEngagement Position as a lifecycle partner for healthcare systems by combining generics strength with branded and biosimilar initiatives, appealing to hospitals, clinics, and group purchasing organizations seeking cost-effective, high-quality medicines.

TechAdvantage Highlight the advanced tech footprint (Oracle HCM Cloud, Coupa P2P, Power Platform) to support efficient order processing, supply chain transparency, and data-driven collaboration with customers for improved dosing, packaging, and compliance solutions.